Navigation Links
Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity,of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO

to be forward-looking statements. There are a number of important factors that could cause the results of Kosan to differ materially from those indicated by these forward-looking statements, including, among others, risks related to the development of Kosan's Hsp90 inhibitors, including the risk that studies may not demonstrate safety and efficacy sufficient to initiate clinical trials, continue clinical development, obtain the requisite regulatory approvals or to result in a marketable product; and other risks detailed from time to time in the Company's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2007, and other periodic filings with the SEC. Kosan does not undertake any obligation to update forward-looking statements.

Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.

CONTACT: Jane Green, VP of Corporate Communications for Kosan BiosciencesIncorporated, +1-510-731-5335, mobile, +1-415-652-4819, green@kosan.com

Web site: http://www.kosan.com/

Ticker Symbol: (NASDAQ-NMS:KOSN)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
5. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:1/15/2014)... IRVING, Texas , Jan. 15, 2014  Novation, the ... company, awarded several new IT value-added reseller (VAR) national ... with IT goods and services at lower costs. These ... value-added services such as initiative assistance and ongoing IT ...
(Date:1/15/2014)... 2014 Massachusetts General Hospital (MGH), the Broad ... announced today that they have launched a strategic ... targets and develop novel therapies for inflammatory bowel ... worldwide. The MGH-Broad-Amgen collaboration brings together scientists with ...
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014  Humberto ... in Dermatology Achievement Award" from the Journal of ... Dermatology Aesthetic & Clinical Conference (ODAC). The event is January ... Florida . The ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... 17 Innocoll, Inc., a privately-held,biopharmaceutical company, ... phase,2 clinical trials sponsored by its wholly ... GENTAMICIN TOPICAL for the,treatment and prevention of ... GENTAMICIN TOPICAL is a biodegradable and fully ...
... Biosciences,Incorporated (Nasdaq: KOSN ) presented preclinical data ... in vitro and in vivo,activity as well as ... NEI anticancer mechanism of action correlating inhibition,of the ... cancer cells,compared to normal cells. Data on Kosan,s ...
Cached Medicine Technology:Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 2Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 4Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 2Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 3Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 4
(Date:4/23/2014)... 2014 The American Society for Radiation Oncology (ASTRO) ... Postoperative Radiation Therapy for Endometrial Cancer: An ASTRO ... radiation therapy in the treatment of endometrial cancer. ... May-June 2014 issue of Practical Radiation Oncology ... ASTRO. The full-length guideline is available as an ...
(Date:4/23/2014)... pathway that helps prevent new cells from receiving too ... been directly linked to cancer and other diseases. , ... the end of cell division, the enzyme Cdc14 activates ... are fully repaired before the parent cell distributes copies ... safeguard against some of the most devastating genome errors, ...
(Date:4/23/2014)... April 23, 2014Men whose testosterone falls below normal levels ... be overweight and have heart disease and type 2 ... testosterone-deficient men for further testing and possible treatment is ... Health , a peer-reviewed publication from Mary Ann Liebert, ... Journal of Men,s Health website at ...
(Date:4/23/2014)... The American Gastroenterological Association (AGA) Research Foundation ... Scholars. The AGA Research Scholar Awards program, launched ... and productive research careers in digestive diseases. This ... additional year allowing for three consecutive years of ... faculty who are paving the way for promising ...
(Date:4/23/2014)... In a country as wealthy as the United States, it ... do not have access to adequate food due to lack ... , Recent research at the University of Illinois using ... revealed that the seniors who are dealing with hunger are ... 2011, 8.35 percent of Americans over age 60 faced the ...
Breaking Medicine News(10 mins):Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2Health News:AGA announces 2014 Class of AGA Research Scholars 2Health News:More Americans in their golden years are going hungry 2
... C. Novelli as MDMA,s Director of Federal Affairs, ... Association (MDMA) is pleased to announce the appointment ... Federal Affairs., (Photo: http://www.newscom.com/cgi-bin/prnh/20041004/MDMALOGO ), ... US Senate Committee on Finance,for Senator Charles Grassley ...
... agencies and scientists are tirelessly working to make manned ... Mars a reality. The technologies involved are awe-inspiring, but ... to face in an era of interplanetary exploration and, ... the European Science Foundation (ESF), European Space Agency (ESA) ...
... September 13 Elsevier today announced the,appointment ... and Government,Sales and Customer Marketing. In this ... marketing organization working directly with universities and,institutions ... research information,solutions, including ScienceDirect, Scopus, bibliographic databases ...
... 13 NuVasive, Inc. (Nasdaq:,NUVA), a medical device ... treatments for the spine, announced today,that Keith Valentine, ... Vice President and Chief Financial Officer, are,scheduled to ... at the St. Regis Hotel, in San Francisco, ...
... Latest SafeTrace Tx(R) User, DENVER, Sept. 13 ... today announced that its Wyndgate,Technologies(R) division has licensed ... of Puerto Rico and the Caribbean (CCPRC) to ... not disclosed. (Logo: http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO ) ...
... Customize Wellness and Care Management Solutions for their ... Workforces, Consultative tailoring initially offered to customer ... ... market,success with employer wellness products such as Healthy Blue Living(SM) and,Healthy Blue Incentives(SM), Blue Cross ...
Cached Medicine News:Health News:MDMA Names New Director of Federal Affairs 2Health News:Space scientists, humanist scholars to explore outer space from new perspective 2Health News:Space scientists, humanist scholars to explore outer space from new perspective 3Health News:Roy Jakobs Appointed Elsevier Managing Director, A&G Sales and Customer Marketing 2Health News:NuVasive to Present at ThinkEquity Partners 5th Annual Growth Conference 2Health News:NuVasive to Present at ThinkEquity Partners 5th Annual Growth Conference 3Health News:Global Med Technologies(R) Extends Its Worldwide Outreach 2Health News:Global Med Technologies(R) Extends Its Worldwide Outreach 3Health News:Blue Cross Blue Shield of Michigan Offers New Approach to Customer Group Wellness 2Health News:Blue Cross Blue Shield of Michigan Offers New Approach to Customer Group Wellness 3
... Nellcor NPB-290 and NPB-295 Pulse Oximeters ... provide accuracy, reliability and proven signal ... poorly perfused patients. Equipped with Oxismart ... Technology, these pulse oximeters identify electronic ...
The Model 5340 is intended for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring....
The Model 340DT is a new desk top pulse oximeter that was designed for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring....
... The Model 130 has expanded memory capabilities ... has memory to retain oxygen saturation and pulse ... modes to best suit your needs:, ,1. ... minutes of information for a single patient, making ...
Medicine Products: